- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03783884
En protokoll som sammenligner temporær transvenøs diafragma-pacing med standard for omsorg for avvenning fra mekanisk ventilasjon (RESCUE 3)
En randomisert, kontrollert, åpen merket, multisenter klinisk studie for å evaluere sikker og effektiv ytelse av lungepacer-diafragma-pacing-terapisystemet hos pasienter som ikke har klart å avvenne fra mekanisk ventilasjon.
This clinical investigation is an open-label, multi-center, randomized clinical trial (RCT) to demonstrate the safety and effective performance of the Lungpacer DPTS (plus standard of care) as compared to Control (standard of care only) in patients aged 18 years or older who are receiving mechanical ventilation. Eligible Subjects will have received mechanical ventilation for ≥96 hours (4 days) and have failed two weaning attempts.
The goal or outcome is to show a numerically greater proportion of subjects weaned in the Treatment (Lungpacer DPTS) group as compared to the Control group.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
The intended patient population is applicable for Lungpacer Diaphragm Pacing Therapy (DPT) because there are no noninvasive alternative treatments for patients who are difficult to wean from MV (i.e., ≥96 hours (4 days) on MV) or who have required prolonged MV (>7 days). The intended patient population includes approximately one-third of all patients on mechanical ventilation. Under standard of care, approximately 50% of these patients will recover from mechanical ventilation (Jung, 2016). Standard of care involves daily weaning attempts, known as Spontaneous Breathing Trials (SBTs) or Ventilator Liberation Trials (VLTs) that are intended to encourage diaphragm use and strengthening over time.Therefore, Lungpacer DPT efficacy evaluation must be compared to standard of care in a Control group. Lack of recovery from mechanical ventilation may be due to the inability of a patient to participate in VLTs or weaning attempts, due to extensive diaphragm weakness or sedation, the inability of VLTs to induce sufficient diaphragm strengthening, or co-morbidities that prevent recovery.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
California
-
Stanford, California, Forente stater, 94305
- Stanford University Medical Center
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- University of Colorado Anschutz Medical Campus
-
-
Florida
-
Gainesville, Florida, Forente stater, 32610
- University of Florida, Shands
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60612
- Rush University Medical Center
-
Chicago, Illinois, Forente stater, 60611
- Northwestern University Feinberg School of Medicine
-
Chicago, Illinois, Forente stater, 60612
- U of Illinois at Chicago
-
Hines, Illinois, Forente stater, 60141
- Edward Hines VA Hospital
-
Maywood, Illinois, Forente stater, 60153
- Loyola University Medical Center
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Indiana University Health Methodist Hospital
-
-
Kentucky
-
Louisville, Kentucky, Forente stater, 40202
- University of Louisville
-
-
Massachusetts
-
Burlington, Massachusetts, Forente stater, 01805
- Lahey Hospital and Medical Center
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55407
- Minneapolis Heart Institute Foundation
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68124
- CHI Health Creighton University Medical Center - Bergan Mercy
-
-
New Jersey
-
Englewood, New Jersey, Forente stater, 07631
- Englewood Hospital Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45267
- University of Cincinnati
-
Cleveland, Ohio, Forente stater, 44195
- Cleveland Clinic Foundation
-
Columbus, Ohio, Forente stater, 43210
- Ohio State University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forente stater, 19140
- Temple University Hospital
-
-
Rhode Island
-
Warwick, Rhode Island, Forente stater, 02886
- Kent County Memorial Hospital
-
-
South Carolina
-
Columbia, South Carolina, Forente stater, 29203
- Prisma Health Baptist Hospital
-
-
Texas
-
Dallas, Texas, Forente stater, 75390
- University of Texas Southwestern, Zale Lipshy Hospital
-
-
Utah
-
Salt Lake City, Utah, Forente stater, 84132
- University of Utah
-
-
-
-
-
Angers, Frankrike, 49933
- CHU Angers
-
Montpellier, Frankrike, 34295
- CHU Montpellier
-
Paris, Frankrike, 75651
- Hôpital La Pitié-Salpêtrière
-
Strasbourg, Frankrike, 67091
- CHU Strasbourg
-
-
-
-
-
Berlin, Tyskland, 10117
- Berlin Charite Mitte
-
Essen, Tyskland, 45276
- KEM Essen
-
Löwenstein, Tyskland, 74245
- SLK Löwenstein
-
Nuremberg, Tyskland, 90419
- Nürnberg Klinikum Nord
-
Schmallenberg, Tyskland, 57392
- FKKG Schmallenberg
-
Solingen, Tyskland, 42699
- Solingen Krankenhaus Bethanien
-
-
Mecklenburg-Vorpommern
-
Greifswald, Mecklenburg-Vorpommern, Tyskland, 17475
- Universitätsmedizin Greifswald
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Are 18 years or older, and,
- Have been mechanically ventilated for ≥96 hours (4 days), and,
- Have satisfied the Readiness-to-Wean criteria, and,
- Have failed at least 2 weaning attempts (that were conducted at least 48 hours after initiation of MV, and, that were conducted on different calendar days, and, at least one of which was the protocol-specific Ventilator Liberation Trial).
Exclusion Criteria:
- Maximal Inspiratory Pressure (MIP) (absolute value) >50 cm H2O;
- Invasive mechanical ventilation >90 days;
- Currently on extracorporeal membrane oxygenation (ECMO);
- Weaning failure due to hypervolemia;
- Medical history (including imaging) or known anatomy that prevents percutaneous insertion of the Catheter into the intended thoracic vein on the left side.
- Clinically overt congestive heart failure that is preventing weaning;
- Currently being treated with neuromuscular blockade;
- Pre-existing neurological, neuromuscular or muscular disorder that could affect the respiratory muscles;
- Pre-existing severe chronic pulmonary fibrosis;
- Pleural effusions occupying greater than one third of the pleural space on either side;
- BMI >45 kg/m2;
- Known or suspected phrenic nerve paralysis;
- Any electrical device (implanted or external) that may be prone to interaction with, or interference from the Lungpacer DPTS including neurological pacing/stimulator devices, cardiac pacemakers and defibrillators;
- Current hemodynamic instability, sepsis or septic shock;
- Prior bacteremia reported within the last 48 hours;
- Anticipating withdrawal of life support and/or shift to palliation as the goal of care;
- Known or suspected to be pregnant or lactating;
- Currently being treated in another clinical trial studying an experimental treatment that could affect the study primary outcome.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Treatment
Subject receives Lungpacer Catheter for transvenous phrenic nerve stimulation to deliver Diaphragm Pacing Therapy Sessions. DPT sessions are 6 sets of 10, delivered twice daily, for a total of 120 stimulation reps per day, plus standard of care for weaning from mechanical ventilation. |
Transvenous phrenic nerve stimulation to induce diaphragm contraction.
Andre navn:
|
|
Ingen inngripen: Control
Subject does not receive Lungpacer Catheter or DPT. Subject receives only Standard of care for weaning from mechanical ventilation. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Successful Weaning
Tidsramme: Through Day 30
|
Cumulative percentage of subjects successfully weaned by Day 30. |
Through Day 30
|
|
Adverse Event Profile
Tidsramme: 30 days
|
Characterize the adverse event profile to support an observed consistent risk profile for subjects randomized to Treatment compared to subjects randomized to Control. Percentage of subjects with adverse events (AE) and serious adverse events (SAE) were summarized for the Treatment group and the Control group by system organ class (SOC) and lower level term. No formal statistical hypothesis test or criterion for the primary safety endpoint was defined. |
30 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Days on Mechanical Ventilation (MV)
Tidsramme: Successful weaning or Day 30
|
The average days on mechanical ventilation from Day 1 to removal from MV associated with successful weaning or Day 30, whichever comes first, will be statistically significantly smaller for subjects randomized to Treatment as compared to subjects randomized to Control. |
Successful weaning or Day 30
|
|
Maximal Inspiratory Pressure (MIP) Change
Tidsramme: Baseline last available measure through Day 30.
|
The mean improvement in inspiratory muscle strength as shown by the change in Maximal Inspiratory Pressure (MIP) from randomization to last available measure in subjects randomized to Treatment is superior to that in subjects randomized to Control. |
Baseline last available measure through Day 30.
|
|
Rapid Shallow Breathing Index (RSBI) Change
Tidsramme: Baseline to last available measure through Day 30.
|
To determine change in Rapid Shallow Breathing Index (RSBI) from randomization to last available measure in subjects randomized to Treatment as compared to Control. RSBI measures the ratio of the respiratory rate to Tidal Volume in breaths/min/L and is commonly used as an index for weaning success. A reduction in RSBI is considered as clinical improvement. |
Baseline to last available measure through Day 30.
|
|
Survival
Tidsramme: 30 days
|
Cumulative percentage of subjects who survived through Day 30. |
30 days
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Re-instatements of MV (After Successful Weaning) Through Day 30.
Tidsramme: Through Day 30.
|
Assessment of re-instatements of MV in subjects who were successful weaned through Day 30 in the Treatment group as compared to the Control group. |
Through Day 30.
|
|
Tracheotomy After Randomization
Tidsramme: Through 30 days
|
Assessment of percentage of subjects after randomization to Day 30 that required tracheostomy in the Treatment group as compared to the Control group. |
Through 30 days
|
|
ICU Discharges to Day 30.
Tidsramme: through 30 days
|
Assessment of ICU discharges to Day 30 in the Treatment group as compared to the Control group. |
through 30 days
|
|
Hospital Discharges to Day 30.
Tidsramme: through 30 days
|
Assessment of hospital admissions and discharges to Day 30 in the Treatment group as compared to the Control group. |
through 30 days
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- P-300
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Only investigators participating in this clinical trial will be able to see final de-identified participant data at the completion of the study.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .